Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von J B Readman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infection and Immunity, St George's, University of London, London, UK. Hauptthemen laut MEDLINE: Amikacin, Neonatal Sepsis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UK Medical Research Council.
Themen: Sepsis
Abstract (Originalsprache)
Background
Infection with ESBL-producing Enterobacteriaceae infection is ubiquitous in some neonatal ICUs and increasing levels of antibiotic resistance are a cause for urgent concern. Delineation of bacterial and viral sepsis can be challenging, often leading to patients receiving empirical antibiotics without or whilst waiting for a definitive causal diagnosis. Empirical therapy is often dependent on broad-spectrum ‘Watch’ antibiotics, contributing to further resistance.
Methods
ESBL-producing Enterobacteriaceae clinical isolates found to have caused neonatal sepsis and meningitis underwent a detailed in vitro screening including susceptibility testing, chequerboard combination analysis and hollow-fibre infection model dynamic analyses using combinations of cefotaxime, ampicillin and gentamicin in combination with β-lactamase inhibitors.
Results
Additivity or synergy was found for all antibiotic combinations against seven Escherichia coli and three Klebsiella pneumoniae clinical isolates. Cefotaxime or ampicillin plus sulbactam combined with gentamicin was able to consistently inhibit the growth of ESBL-producing isolates at typical neonatal doses, and the combination cleared the hollow-fibre infection model system of organisms resistant to each agent alone. The combination of cefotaxime/sulbactam and gentamicin was consistently bactericidal at clinically achievable concentrations (Cmax of 180, 60 and 20 mg/L for cefotaxime, sulbactam and gentamicin, respectively).
Conclusions
The addition of sulbactam to cefotaxime or ampicillin to the typical first-line empirical therapy could obviate the need for carbapenems and amikacin in settings with high ESBL-infection prevalence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Infection and Immunity, St George's, University of London, London, UK.
- Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, London, UK.
- UCL Genetics Institute, University College London, London, UK.
- Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
- Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.
ORCID-Profile: J F Standing
Förderung
- Medical Research Council
- UK Medical Research Council
Zitieren
APA
Readman, J. B., Acman, M., Hamawandi, A., Chiu, C. H., Sharland, M., Lindsay, J. A., & Standing, J. F. (2023). Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad177
Vancouver
Readman JB, Acman M, Hamawandi A, Chiu CH, Sharland M, Lindsay JA, et al. Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad177
BibTeX
@article{Readman2023,
author = {Readman, J B and Acman, M and Hamawandi, A and Chiu, Cheng-Hsun and Sharland, M and Lindsay, J A and Standing, J F},
title = {Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad177}
}
EUVIMED